Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 14/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.61 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafoxidine SCHEMBL10563464 | 1.00 | EBP (1.00) | EBPSIGMAR1ESR1ESR2LTA4H | |
| Nafoxidine SCHEMBL153125 | 1.00 | EBP (1.00) | EBPSIGMAR1ESR1ESR2LTA4H | |
| Nafoxidine SCHEMBL115778 | 0.99 | EBP (0.98) | EBPSIGMAR1ESR1ESR2LTA4H | |
| Nafoxidine SCHEMBL8430193 | 0.99 | EBP (0.98) | EBPSIGMAR1ESR1ESR2LTA4H | |
| Nafoxidine SCHEMBL29562423 | 0.99 | EBP (0.98) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL8015672 | 0.94 | EBP (0.88) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL2811903 | 0.94 | EBP (0.88) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL2811811 | 0.93 | EBP (0.86) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL13350303 | 0.93 | EBP (0.86) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL2817373 | 0.93 | EBP (0.86) | EBPSIGMAR1ESR1ESR2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12383634-B2 | Single domain antibody targeting αVβ3 integrin | KOREA BASIC SCIENCE INSTITUTE (KR) | 2025-08-12 | — | — | US | disclosed |
| WO-2025019823-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024241248-A1 | COMPOUNDS TARGETING KRAS G12D MUTATIONS AND THEIR USES | INNOPHARMASCREEN INC. (KR) | 2024-11-28 | — | — | WO | disclosed |
| EP-4448526-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240293487-A1 | IMMUNOEVASIVE ANTI-TUMOR ADENOVIRUS | CURIGIN CO., LTD. (KR) | 2024-09-05 | — | — | US | disclosed |
| WO-2023215256-A1 | SOS1 INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-116621833-A | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-115996723-A | Oral formulations and uses thereof | 益方生物科技(上海)股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-109563155-B | Antibodies, compositions and kits comprising the same, and methods of use thereof | 北京伟德杰生物科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-4148126-A1 | IMMUNOEVASIVE ANTI-TUMOR ADENOVIRUS | Curigin Co.,Ltd. (KR) | 2023-03-15 | — | — | EP | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114901662-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-112638419-B | Modified CTLA4 and methods of use thereof | 北京伟德杰生物科技有限公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2022125949-A1 | USE OF PSILOCYBIN IN CANCER TREATMENT | SILO PHARMA, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220133913-A1 | SINGLE DOMAIN ANTIBODY TARGETING aVB3 INTEGRIN | KOREA BASIC SCIENCE INSTITUTE (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11291722-B2 | Vaccine composition comprising cyclic peptides, antibodies to the cyclic peptides or an anticancer composition comprising the same | INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIVERSITY (KR) | 2022-04-05 | — | — | US | disclosed |